Pseudotargeted Lipidomics Analysis of Scoparone on Glycerophospholipid Metabolism in Non-alcoholic Steatohepatitis Mice by LC-MRM-MS

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2024 May 27

PMID 38799063

Authors

Qi Song

Ziyi Zhao

Hu Liu

Jinling Zhang

Zhiqiang Wang

Yunqi Zhang

Guowei Ma

Shaoqin Ge

Affiliations

Soon will be listed here.

Abstract

As the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD), the progression of nonalcoholic steatohepatitis (NASH) is associated with disorders of glycerophospholipid metabolism. Scoparone is the major bioactive component in which has been widely used to treat NASH in traditional Chinese medicine. However, the underlying mechanisms of scoparone against NASH are not yet fully understood, which hinders the development of effective therapeutic agents for NASH. Given the crucial role of glycerophospholipid metabolism in NASH progression, this study aimed to characterize the differential expression of glycerophospholipids that is responsible for scoparone's pharmacological effects and assess its efficacy against NASH. Liquid chromatography-multiple reaction monitoring-mass spectrometry (LC-MRM-MS) was performed to get the concentrations of glycerophospholipids, clarify mechanisms of disease, and highlight insights into drug discovery. Additionally, pathologic findings also presented consistent changes in high-fat diet-induced NASH model, and after scoparone treatment, both the levels of glycerophospholipids and histopathology were similar to normal levels, indicating a beneficial effect during the observation time. Altogether, these results refined the insights on the mechanisms of scoparone against NASH and suggested a route to relieve NASH with glycerophospholipid metabolism. In addition, the current work demonstrated that a pseudotargeted lipidomic platform provided a novel insight into the potential mechanism of scoparone action.

Citing Articles

The immunoregulatory effects of scoparone on immune-mediated inflammatory diseases.

Qiu F, Lin J, Huang X, Yang B, Lu W, Dai Z Front Immunol. 2025; 16:1518886.

PMID: 39958341 PMC: 11825328. DOI: 10.3389/fimmu.2025.1518886.

References

Paul B, Lewinska M, Andersen J . Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 2022; 4(6):100479. PMC: 9034302. DOI: 10.1016/j.jhepr.2022.100479. View

Li Z, Agellon L, Allen T, Umeda M, Jewell L, Mason A . The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 2006; 3(5):321-31. DOI: 10.1016/j.cmet.2006.03.007. View

Liu X, Zhao X . Scoparone attenuates hepatic stellate cell activation through inhibiting TGF-β/Smad signaling pathway. Biomed Pharmacother. 2017; 93:57-61. DOI: 10.1016/j.biopha.2017.06.006. View

Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal A . Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2021; 18(6):373-392. DOI: 10.1038/s41575-020-00408-y. View

Zhang A, Qiu S, Sun H, Zhang T, Guan Y, Han Y . Scoparone affects lipid metabolism in primary hepatocytes using lipidomics. Sci Rep. 2016; 6:28031. PMC: 4910084. DOI: 10.1038/srep28031. View

Elblehi S, Hafez M, El-Sayed Y . L-α-Phosphatidylcholine attenuates mercury-induced hepato-renal damage through suppressing oxidative stress and inflammation. Environ Sci Pollut Res Int. 2019; 26(9):9333-9342. DOI: 10.1007/s11356-019-04395-9. View

Liu B, Deng X, Jiang Q, Li G, Zhang J, Zhang N . Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS/P38/Nrf2 axis and PI3K/AKT/mTOR pathway in macrophages. Biomed Pharmacother. 2020; 125:109895. DOI: 10.1016/j.biopha.2020.109895. View

Kim Y, Seok S, Byun S, Kong B, Zhang Y, Guo G . AhR and SHP regulate phosphatidylcholine and S-adenosylmethionine levels in the one-carbon cycle. Nat Commun. 2018; 9(1):540. PMC: 5803255. DOI: 10.1038/s41467-018-03060-y. View

Trovato F, Zia R, Napoli S, Wolfer K, Huang X, Morgan P . Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation. Hepatology. 2021; 74(2):907-925. DOI: 10.1002/hep.31738. View

10.

Fu S, Yang L, Li P, Hofmann O, Dicker L, Hide W . Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature. 2011; 473(7348):528-31. PMC: 3102791. DOI: 10.1038/nature09968. View

11.

Noh J, Kim Y, Hwang J, Gang G, Yeo S, Kim K . Scoparone inhibits adipocyte differentiation through down-regulation of peroxisome proliferators-activated receptor γ in 3T3-L1 preadipocytes. Food Chem. 2013; 141(2):723-30. DOI: 10.1016/j.foodchem.2013.04.036. View

12.

Kitagawa E, Yamamoto T, Yamamoto K, Nakagawa T, Hayakawa T . Accumulation of lipid in rat liver was induced by vitamin B₆ deficiency and was ameliorated by supplemental phosphatidylcholine in the diet. Biosci Biotechnol Biochem. 2015; 79(8):1320-6. DOI: 10.1080/09168451.2015.1020755. View

13.

Sheka A, Adeyi O, Thompson J, Hameed B, Crawford P, Ikramuddin S . Nonalcoholic Steatohepatitis: A Review. JAMA. 2020; 323(12):1175-1183. DOI: 10.1001/jama.2020.2298. View

14.

van der Veen J, Kennelly J, Wan S, Vance J, Vance D, Jacobs R . The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta Biomembr. 2017; 1859(9 Pt B):1558-1572. DOI: 10.1016/j.bbamem.2017.04.006. View

15.

Walker A, Jacobs R, Watts J, Rottiers V, Jiang K, Finnegan D . A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell. 2011; 147(4):840-52. PMC: 3384509. DOI: 10.1016/j.cell.2011.09.045. View

16.

Ratziu V, Francque S, Sanyal A . Breakthroughs in therapies for NASH and remaining challenges. J Hepatol. 2022; 76(6):1263-1278. DOI: 10.1016/j.jhep.2022.04.002. View

17.

Kawano Y, Nishiumi S, Saito M, Yano Y, Azuma T, Yoshida M . Identification of Lipid Species Linked to the Progression of Non-Alcoholic Fatty Liver Disease. Curr Drug Targets. 2015; 16(12):1293-300. DOI: 10.2174/1389450116666150408103318. View

18.

Sayiner M, Lam B, Golabi P, Younossi Z . Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2018; 11:1756284818811508. PMC: 6243399. DOI: 10.1177/1756284818811508. View

19.

Alcoriza-Balaguer M, Garcia-Canaveras J, Lopez A, Conde I, Juan O, Carretero J . LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics. Anal Chem. 2018; 91(1):836-845. DOI: 10.1021/acs.analchem.8b03409. View

20.

Payne F, Lim K, Girousse A, Brown R, Kory N, Robbins A . Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. Proc Natl Acad Sci U S A. 2014; 111(24):8901-6. PMC: 4066527. DOI: 10.1073/pnas.1408523111. View